Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Ruzurgi amifampridine Lambert-Eaton myasthenic syndrome Reimburse with clinical criteria and/or conditions Complete
Firdapse amifampridine phosphate Lambert-Eaton Myasthenic Syndrome, adults Reimburse with clinical criteria and/or conditions Complete
Rybrevant amivantamab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Caduet Amlodipine besylate/ atorvastatin calcium Hypertension/ Dyslipidemia List with clinical criteria and/or conditions Complete
Kineret anakinra Still's disease Withdrawn
Ondexxya andexanet alfa Reversal of FXa inhibitor anticoagulant effects Do not reimburse Complete
Saphnelo anifrolumab Systemic lupus erythematosus Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide metastatic castration-sensitive prostate cancer (mCSPC) Reimburse with clinical criteria and/or conditions Complete
Erleada Apalutamide non-metastatic castrate resistant prostate cancer (nm-CRPC) Reimburse with clinical criteria and/or conditions Complete
Eliquis Apixaban Venous thromboembolic events, prevention List with clinical criteria and/or conditions Complete